Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Organic Chemical
>
Methylprednisolone
Methylprednisolone
Methylprednisolone is a synthetic glucocorticoid drug used for its anti-inflammatory and immunosuppressant properties.
It is commonly prescribed for a variety of conditions, including asthma, rheumatoid arthritis, multiple sclerosis, and organ transplant rejection.
Methylprednisolone works by reducing inflammation and suppressing the immune system.
It is available in oral, injectable, and topical formulations.
Researchers studying methylprednisolone can use PubCompare.ai to optimize their research workflow by easily locating the most relevant protocols from literature, preprints, and patents, while receiving accurate comparisons to identify the best processes and products.
This can enhance reproducbility and accuracy in methylprednisolone studies.
It is commonly prescribed for a variety of conditions, including asthma, rheumatoid arthritis, multiple sclerosis, and organ transplant rejection.
Methylprednisolone works by reducing inflammation and suppressing the immune system.
It is available in oral, injectable, and topical formulations.
Researchers studying methylprednisolone can use PubCompare.ai to optimize their research workflow by easily locating the most relevant protocols from literature, preprints, and patents, while receiving accurate comparisons to identify the best processes and products.
This can enhance reproducbility and accuracy in methylprednisolone studies.
Most cited protocols related to «Methylprednisolone»
Adenovirus Infections
Adrenal Cortex Hormones
Antibiotics
Bacteria
Biological Assay
Blood
Bronchi
Bronchoalveolar Lavage Fluid
Complete Blood Count
COVID 19
Creatine Kinase
Electrolytes
Feces
Genes, env
Influenza
Influenza in Birds
isolation
Kidney
Lactate Dehydrogenase
Liver
Mechanical Ventilation
Methylprednisolone
Middle East Respiratory Syndrome Coronavirus
Nasal Cannula
Nose
Oligonucleotide Primers
Oseltamivir
Oxygen
Parainfluenza
Pathogenicity
Patients
Pharynx
Physical Examination
Physicians
Pneumonia
Real-Time Polymerase Chain Reaction
Respiratory Rate
Respiratory Syncytial Virus
Respiratory System
SARS-CoV-2
Serum
Severe acute respiratory syndrome-related coronavirus
Sputum
Tests, Blood Coagulation
Tests, Diagnostic
Therapeutics
Treatment Protocols
Virus
Virus Release
The IMPACT database includes patients with moderate and severe TBI (GCS ≤ 12) from eight randomized controlled trials and three observational studies conducted between 1984 and 1997 [11 (link)]. Detailed characteristics of these 11 studies and data management have been described previously [15 (link)]. The endpoint for the prognostic analyses was the 6 mo GOS, which is an ordered outcome with five categories: 1, dead; 2, vegetative state; 3, severe disability; 4, moderate disability; and 5, good recovery. In patients whose 6 mo assessment was not available we used the 3 mo GOS (n = 1,611, 19% of the patients). We selected 8,509 patients aged ≥ 14 y [12 (link)].
We externally validated prognostic models using patients enrolled in the Medical Research Council Corticosteroid Randomisation after Significant Head Injury (MRC CRASH) trial (trial registration ISRCTN74459797, ISRCTN Register,http://www.controlled-trials.com/ ), who were recruited between 1999 and 2004 [13 (link)]. This was a large international double-blind, randomized placebo-controlled trial of the effect of early administration of a 48-h infusion of methylprednisolone on outcome after head injury. It was found that the risks of death and disability were higher in the corticosteroid group than in the placebo group. The trial included 10,008 adults with GCS ≤ 14, who were enrolled within 8 h after injury. We selected 6,681 patients with a GCS ≤ 12 and with complete 6 mo GOS. Secondary analyses considered only placebo patients (n = 3,287) and patients from high-income countries (n = 1,588). For the validation we focused on prediction of mortality (GOS 1) versus survival (GOS 2–5) and of unfavorable (GOS 1–3) versus favorable outcome (GOS 4–5).
We externally validated prognostic models using patients enrolled in the Medical Research Council Corticosteroid Randomisation after Significant Head Injury (MRC CRASH) trial (trial registration ISRCTN74459797, ISRCTN Register,
Adrenal Cortex Hormones
Adult
Craniocerebral Trauma
Disabled Persons
Injuries
Methylprednisolone
Patients
Placebos
Vegetative State
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Adenovirus Infections
Agglutination
Antibiotics
Antigens, Viral
Azithromycin
Blood Culture
Child
Children's Health
Chlamydophila pneumoniae
Clindamycin
Enzyme Immunoassay
Erythromycin
Fever
Immunoglobulin M
Macrolides
Males
Meridians
Methylprednisolone
Minocycline
Mycoplasma
Mycoplasma pneumoniae
Nasopharynx
Orthomyxoviridae
pathogenesis
Patients
Pneumonia
Pulse Rate
Radiography, Thoracic
Respiratory Rate
Respiratory System
Respiratory Tract Infections
Serum
Virus
Woman
X-Rays, Diagnostic
denileukin diftitox
Disease Progression
Etanercept
Methylprednisolone
Mycophenolate Mofetil
Patients
Pentostatin
Prednisone
Steroids
Therapeutics
Azathioprine
Body Surface Area
Body Weight
Cyclophosphamide
Glucocorticoids
Kidney Failure
Methylprednisolone
Patients
Placebos
Prednisone
Pulses
Remission Induction
Rituxan
Rituximab
Treatment Protocols
Most recents protocols related to «Methylprednisolone»
A 5-French catheter was inserted into the common hepatic artery via the right femoral artery. Before steroid injection, angiography was performed to detect any anomalies in the hepatic artery. If no replaced hepatic artery was found, the tip of the catheter was set at the proper hepatic artery. If there were 2 hepatic arteries, the catheter was positioned in the branch with the most expansive feeding area. After insertion, 1000 mg of methylprednisolone was infused over 1 hour each day for 3 days, and the catheter was removed immediately after injection on the third day. A once-daily plasma exchange was added to the regimen if a bleeding tendency was observed during this procedure.
Angiography
Blood Coagulation Disorders
Catheters
Femoral Artery
Hepatic Artery
Methylprednisolone
Plasmapheresis
Steroids
Treatment Protocols
All patients were consecutively recruited on the day before surgery. After written informed consent was obtained, baseline questionnaires were completed. Follow-ups after surgery for pain evaluation were performed on postoperative days (POD) 1, 3, 7, 14, 21, and 30 and monthly thereafter until pain resolution was reached or up to 6 months after surgery; the sessions were conducted by face-to-face interviews during the hospital stay or telephone interviews after discharge. Loss to follow-up was defined as the patient not being contacted during two consecutive follow-ups.
A standard perioperative pain management protocol was performed. Multimodal analgesia during surgery included the following: 1) corticosteroids, such as intravenous injection of methylprednisolone 40–80 mg before induction; 2) continuous infusion of dexmedetomidine at a rate of 0.4–0.6 μg/kg/h until incision closure; 3) short-acting opioids, including intermittent intravenous injection of sufentanil with a total dose of 0.5–1.0 μg/kg and continuous infusion of remifentanil 0.1–0.2 μg/kg/min until the end of surgery; and 4) flurbiprofen 100 mg or parecoxib 40 mg intravenously administered before the end of surgery when no contraindication presented. At the end of surgery, patient-controlled intravenous analgesia (PCIA) with sufentanil was provided to each patient for at least 72 hours. The PCIA device was initially set to deliver sufentanil at a rate of 2 μg/hour (solution 1 μg/ml) and a bolus of sufentanil 3 μg on request with a lockout time of 15 minutes. Background infusion was stopped if the worst pain score was <= 3 or opioid-related side effects (such as nausea and vomiting and dizziness) were reported during follow-ups. If severe opioid-related side effects persisted despite pharmacological treatment, PCIA was stopped at the request of the patient.
In wards, nonsteroidal anti-inflammatory drugs or COX-2 inhibitors were used as needed based on the surgeons’ preference. If patients reported pain with neuropathic characteristics, such as numbness and burning, gabapentin was added. Immediate-release oxycodone (5 mg) or tramadol (100 mg) was administered orally for rescue analgesia. Oral sustained-release oxycodone (5 mg every 12 hours) or a transdermal fentanyl patch (25 μg/hour for 72 hours) was provided for persistent severe pain after cessation of PCIA. Pain consultations were held when necessary.
A standard perioperative pain management protocol was performed. Multimodal analgesia during surgery included the following: 1) corticosteroids, such as intravenous injection of methylprednisolone 40–80 mg before induction; 2) continuous infusion of dexmedetomidine at a rate of 0.4–0.6 μg/kg/h until incision closure; 3) short-acting opioids, including intermittent intravenous injection of sufentanil with a total dose of 0.5–1.0 μg/kg and continuous infusion of remifentanil 0.1–0.2 μg/kg/min until the end of surgery; and 4) flurbiprofen 100 mg or parecoxib 40 mg intravenously administered before the end of surgery when no contraindication presented. At the end of surgery, patient-controlled intravenous analgesia (PCIA) with sufentanil was provided to each patient for at least 72 hours. The PCIA device was initially set to deliver sufentanil at a rate of 2 μg/hour (solution 1 μg/ml) and a bolus of sufentanil 3 μg on request with a lockout time of 15 minutes. Background infusion was stopped if the worst pain score was <= 3 or opioid-related side effects (such as nausea and vomiting and dizziness) were reported during follow-ups. If severe opioid-related side effects persisted despite pharmacological treatment, PCIA was stopped at the request of the patient.
In wards, nonsteroidal anti-inflammatory drugs or COX-2 inhibitors were used as needed based on the surgeons’ preference. If patients reported pain with neuropathic characteristics, such as numbness and burning, gabapentin was added. Immediate-release oxycodone (5 mg) or tramadol (100 mg) was administered orally for rescue analgesia. Oral sustained-release oxycodone (5 mg every 12 hours) or a transdermal fentanyl patch (25 μg/hour for 72 hours) was provided for persistent severe pain after cessation of PCIA. Pain consultations were held when necessary.
Full text: Click here
Adrenal Cortex Hormones
Analgesics, Opioid
Anti-Inflammatory Agents, Non-Steroidal
ARID1A protein, human
Cyclooxygenase 2 Inhibitors
Dexmedetomidine
Face
Fentanyl
Flurbiprofen
Gabapentin
Management, Pain
Medical Devices
Methylprednisolone
Multimodal Imaging
Nausea
Neuralgia
Operative Surgical Procedures
Opioids
Oxycodone
Pain
Pain Measurement
parecoxib
Patient-Controlled Analgesia
Patients
Pharmacotherapy
Remifentanil
Sufentanil
Surgeons
Tramadol
Transdermal Patch
A complete history of COVID-19 symptomatology and clinical examination was performed. Laboratory investigations were carried out in the form of complete blood count with differential and inflammatory markers such as CRP (enzyme-linked immunosorbent assay [ELISA]), ferritin (ELISA), LDH (ELISA), and D-dimer (ELISA). Radiological assessment was carried out by CT chest (80-slice CT machine, Prime Aquilion, Toshiba, Tustin, CA, USA). We compared the clinical outcomes of patients with non-severe COVID-19 treated with and without CSs.
The primary outcome was a composite endpoint of need for O2 at day 10, need for hospitalization at day 10, or 28-day mortality. Secondary outcomes were time-to-return to daily activity, change in severity and inflammatory markers course (D-dimer, CRP, LDH, and ferritin) at day 10.
Return-to-daily activity was defined as returns to work, return to their home works for women, return to their previous activities before catching COVID-19. Besides, any adverse drug reactions of CSs therapy were recorded during the study period. As per the study protocol, it was not planned to follow-up on the long-term outcomes of CSs as a low to moderate dose (15 to 30 mg) of methylprednisolone was used for a short period of less than 3 months. Thus, it was not a long-term use. All patients were followed up on day 3, day 10, and every week for 45 days or until recovery or hospitalization, or death. Telephone calls were made whenever patients missed a visit.
The primary outcome was a composite endpoint of need for O2 at day 10, need for hospitalization at day 10, or 28-day mortality. Secondary outcomes were time-to-return to daily activity, change in severity and inflammatory markers course (D-dimer, CRP, LDH, and ferritin) at day 10.
Return-to-daily activity was defined as returns to work, return to their home works for women, return to their previous activities before catching COVID-19. Besides, any adverse drug reactions of CSs therapy were recorded during the study period. As per the study protocol, it was not planned to follow-up on the long-term outcomes of CSs as a low to moderate dose (15 to 30 mg) of methylprednisolone was used for a short period of less than 3 months. Thus, it was not a long-term use. All patients were followed up on day 3, day 10, and every week for 45 days or until recovery or hospitalization, or death. Telephone calls were made whenever patients missed a visit.
Chest
Complete Blood Count
COVID 19
Drug Reaction, Adverse
Enzyme-Linked Immunosorbent Assay
Ferritin
fibrin fragment D
Hospitalization
Inflammation
Methylprednisolone
Patients
Physical Examination
Therapeutics
Women, Working
X-Rays, Diagnostic
The study was open-label. Block randomization was conducted using computer-generated random numbers with block size four and an allocation ratio of 1:1. All participants were subjected to management using the local COVID-19 protocol: MOH protocol version 1.4 November 2020 according to the severity (antipyretics, antivirals, antibiotics, and anticoagulants if required). The enrolled patients were randomized into two groups. The CSs group (the active group) was managed according to the standard protocol in addition to CSs once diagnosed (methylprednisolone 30 mg daily for 1 week in moderate cases, then reduced gradually over 2 weeks). In mild cases, we started 15 mg only.
The control group was subjected only to the standard COVID-19 protocol. Control subjects who worsened (needed O2 supplementation or needed hospitalization were managed according to the standard COVID-19 protocol). Thus, they received CSs after their deterioration (delayed CSs). Every visit patient comes, he/she is asked to bring his/her medications with him/her to follow-up on the utilization of CSs.
The control group was subjected only to the standard COVID-19 protocol. Control subjects who worsened (needed O2 supplementation or needed hospitalization were managed according to the standard COVID-19 protocol). Thus, they received CSs after their deterioration (delayed CSs). Every visit patient comes, he/she is asked to bring his/her medications with him/her to follow-up on the utilization of CSs.
Antibiotics, Antitubercular
Anticoagulants
Antipyretics
Antiviral Agents
Cardiac Arrest
COVID 19
Hospitalization
Methylprednisolone
Patients
Pharmaceutical Preparations
This prospective cohort study included patients who survived hospitalization for COVID-19-associated hyperinflammation. Between March and May 2020, patients hospitalized for COVID-19-associated hyperinflammation in the Zuyderland Medical Centre (ZMC), a large teaching hospital in the Netherlands, were included in the COVID High-intensity Immunosuppression in Cytokine storm syndrome (CHIC) study [14 (link)]. COVID-19-associated hyperinflammation was defined according to a set of criteria: oxygen saturation at rest ≤ 94% or tachypnoea (> 30/min); at least two out of three biomarker criteria: CRP > 100 mg/L, serum ferritin > 900 µg/L at one occasion or a twofold increase of the level at admission within 48 h and D-dimer level > 1500 µg/ [14 (link)]. From March 1st to April 1st 2020, patients were treated with standard of care (control group), consisting of oxygen support, antibiotics, chloroquine and anticoagulation. After April 1st, patients were treated according to the CHIC protocol, which was added to standard of care (treated group). This protocol included two steps: (1) intravenous methylprednisolone 250 mg on day 1, followed by methylprednisolone 80 mg intravenously on days 2–5, and an option for a two-day extension; (2) addition of tocilizumab (single dose, 8 mg/kg body weight intravenous, max 800 mg) in case of lack of improvement or worsening in respiratory status 48 h after starting with methylprednisolone. Results confirming the benefits of this therapeutical strategy during the acute setting of COVID-19-associated hyperinflammation have been published [14 (link)]. All survivors of this study were invited for an ambulatory follow-up visit at the Pulmonology department of ZMC. Patients were excluded if they were unable to visit the outpatient clinic.
Approval was obtained by the Medical Ethical Committee (METC) and the Board of ZMC, the Netherlands (number METCZ20200126). All patients provided written informed consent for the use of their data for this study.
Approval was obtained by the Medical Ethical Committee (METC) and the Board of ZMC, the Netherlands (number METCZ20200126). All patients provided written informed consent for the use of their data for this study.
Full text: Click here
Antibiotics, Antitubercular
Biological Markers
Body Weight
Chloroquine
COVID 19
Cytokine Release Syndrome
Ferritin
fibrin fragment D
Hospitalization
Immunosuppression
Methylprednisolone
Oxygen
Oxygen Saturation
Patients
Respiratory Rate
Serum
Survivors
tocilizumab
Top products related to «Methylprednisolone»
Sourced in United States, Belgium, Italy, China
Methylprednisolone is a synthetic corticosteroid medication used as an anti-inflammatory and immunosuppressant drug. It is primarily used in the treatment of various inflammatory and autoimmune conditions.
Sourced in United States, Denmark, Belgium, Japan, Germany
Solu-Medrol is a sterile powder for injection that contains the active ingredient methylprednisolone sodium succinate, a synthetic glucocorticoid. It is used to prepare a solution for intravenous or intramuscular administration.
Sourced in United States, Germany, Italy, China
Methylprednisolone is a synthetic corticosteroid medication used in the treatment of various medical conditions. It is a white to practically white, odorless, crystalline powder. Methylprednisolone is a glucocorticoid that exhibits anti-inflammatory and immunosuppressive properties.
Sourced in Switzerland, United States, Canada
Simulect is a laboratory equipment product manufactured by Novartis. It is designed for use in scientific research and clinical applications.
Sourced in United States, Germany, China, United Kingdom, Sao Tome and Principe, Macao, Italy, Japan, Canada, France, Switzerland, Israel, Australia, Spain, India, Ireland, Brazil, Poland, Netherlands, Sweden, Denmark, Hungary, Austria, Mongolia
The LPS laboratory equipment is a high-precision device used for various applications in scientific research and laboratory settings. It is designed to accurately measure and monitor specific parameters essential for various experimental procedures. The core function of the LPS is to provide reliable and consistent data collection, ensuring the integrity of research results. No further details or interpretations can be provided while maintaining an unbiased and factual approach.
Sourced in United States, France, Canada, Germany, Ireland, Switzerland
Thymoglobulin is a polyclonal antithymocyte globulin (ATG) product developed by Sanofi. It is a sterile, purified, and concentrated immunoglobulin preparation derived from the plasma of horses immunized with human thymocytes. Thymoglobulin is used as an immunosuppressant to prevent and treat acute rejection in organ transplantation.
Sourced in Japan, United States, United Kingdom, Germany, Switzerland
Prograf is a laboratory equipment product manufactured by Astellas Pharma. It is used to measure and monitor the levels of the immunosuppressant drug tacrolimus in biological samples.
Sourced in United States, Switzerland, Germany, France
Cellcept is a laboratory product manufactured by Roche. It is a cell culture medium used for the maintenance and growth of cells in vitro.
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, India, Spain, Japan, Canada, Poland, France
Lipopolysaccharide is a complex molecule found in the outer membrane of Gram-negative bacteria. It is a key structural component of the bacterial cell wall and plays a crucial role in the interaction between bacteria and their host environments.
More about "Methylprednisolone"
Methylprednisolone, also known as Solu-Medrol, is a synthetic glucocorticoid medication widely used for its potent anti-inflammatory and immunosuppressant properties.
It is commonly prescribed to treat a variety of conditions, including asthma, rheumatoid arthritis, multiple sclerosis, and organ transplant rejection.
Methylprednisolone works by reducing inflammation and suppressing the immune system, making it a valuable tool in the management of autoimmune disorders and inflammatory conditions.
It is available in oral, injectable, and topical formulations, allowing for flexible administration based on the specific needs of the patient.
Researchers studying the effects of methylprednisolone can utilize advanced tools like PubCompare.ai to optimize their research workflow.
This AI-driven platform helps researchers easily locate the most relevant protocols from literature, preprints, and patents, while providing accurate comparisons to identify the best processes and products.
This can enhance the reproducibility and accuracy of methylprednisolone studies, leading to more reliable and impactful research outcomes.
In addition to methylprednisolone, other related terms and compounds that may be of interest include Simulect (basiliximab), a monoclonal antibody used to prevent organ rejection in transplant recipients, and Thymoglobulin, an antithymocyte globulin used to suppress the immune system in transplant patients.
Lipopolysaccharide (LPS), a component of the bacterial cell wall, is also a relevant term as it can induce inflammation and be used to study the anti-inflammatory effects of methylprednisolone.
Additional immunosuppressant drugs like Prograf (tacrolimus) and Cellcept (mycophenolate mofetil) may also be relevant in the context of transplant-related research involving methylprednisolone.
Researchers can leverge the insights and tools provided by PubCompare.ai to enhance the quality, reproducbility, and impact of their methylprednisolone-related studies, ultimately contributing to advancements in the management of various inflammatory and autoimmune conditions.
It is commonly prescribed to treat a variety of conditions, including asthma, rheumatoid arthritis, multiple sclerosis, and organ transplant rejection.
Methylprednisolone works by reducing inflammation and suppressing the immune system, making it a valuable tool in the management of autoimmune disorders and inflammatory conditions.
It is available in oral, injectable, and topical formulations, allowing for flexible administration based on the specific needs of the patient.
Researchers studying the effects of methylprednisolone can utilize advanced tools like PubCompare.ai to optimize their research workflow.
This AI-driven platform helps researchers easily locate the most relevant protocols from literature, preprints, and patents, while providing accurate comparisons to identify the best processes and products.
This can enhance the reproducibility and accuracy of methylprednisolone studies, leading to more reliable and impactful research outcomes.
In addition to methylprednisolone, other related terms and compounds that may be of interest include Simulect (basiliximab), a monoclonal antibody used to prevent organ rejection in transplant recipients, and Thymoglobulin, an antithymocyte globulin used to suppress the immune system in transplant patients.
Lipopolysaccharide (LPS), a component of the bacterial cell wall, is also a relevant term as it can induce inflammation and be used to study the anti-inflammatory effects of methylprednisolone.
Additional immunosuppressant drugs like Prograf (tacrolimus) and Cellcept (mycophenolate mofetil) may also be relevant in the context of transplant-related research involving methylprednisolone.
Researchers can leverge the insights and tools provided by PubCompare.ai to enhance the quality, reproducbility, and impact of their methylprednisolone-related studies, ultimately contributing to advancements in the management of various inflammatory and autoimmune conditions.